SEM 2 EBL FLASHCARDS

0.0(0)
studied byStudied by 4 people
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/99

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

100 Terms

1
New cards

Benefits of pegylated liposomal doxorubicin

  • protects liposomes from detection by phagocytes.

  • enhanced stability

  • increased circulation time

  • prevents opsionisation

2
New cards

how does pegylation prevent opsionisation

steric hinderance.

Peg chains create a steric barrier which prevents liposomes being coated with opsionins

3
New cards

what is opsionisation

the process by which pathogens are marked for destruction by the immune system through the binding of opsonins.

4
New cards

What is passive targeting

EPR mediated drug accumulation

5
New cards

what is the EPR effect

Preferential accumulation of nanoparticles in tumour tissue because of their leaky vasculature and insufficient lymphatic drainage.

6
New cards

things to consider when prescribing amongst various groups of people

communication

language barriers

education level

financial status if necessary

patient preference

7
New cards

examples of social prescribing

support groups

physical activity services

8
New cards

Role of cholesterol in liposomal formulation

integrates into liposomal membrane. Improves encapsulation, stability and rigidity

9
New cards

role of sucrose in liposomal formulation

prevents aggregation

10
New cards

role of ammonium sulfate in liposomal formulation

for active loading of drug into liposomes increases drug entrapment efficiency.

11
New cards

role of water for injections in liposomal formulation

solvent

12
New cards

what is the active ingredient in tumeric , what does it do, why is it unsuitable alongside some cancer treatment regimens?

  • active ingredient is curcumin- anti oxidant properties.

  • can interfere with efficacy of some cancer drugs as is a substrate for CYPa 3a4, therefore may increase the exposure of some chemotherapeutics, and increase adverse effects.

13
New cards

MOA- trastuzumab

binds to extracellular ligand binding domain of HER 2 receptor, blocking its activation and therefore stops downstream signalling of the PI3K and MAPK pathways.

Also affects immune cells through antibody dependent cellular cytotoxicity to destroy cancer cells.

14
New cards

What is the HER 2 receptor

Growth factor. Transmembrane tyrosine kinase receptor which is activated by the formation of dimers with other EGFR proteins- activates downstream signalling pathways such as MAPK, PI3K which promote cell growth and survival.

15
New cards

administration of trastuzumab

  • IV over 90mins

  • S/C over 2-5 mins

  • need adequate contraception during and 7 months after treatment.

16
New cards

what is trastuzumab used in

HER 2 positive breast cancer

gastric cancer

17
New cards

Lapatanib MOA

inhibits tyrosine kinase HER 2 receptor through phosphorylation → decreased cell proliferation and survival.

Competes with ATP to block HER 2 signalling and disrupts downstream signalling pathways.

18
New cards

Why is being overweight a risk factor for breast cancer

  • increased adipose tissue in overweight.

  • Aromatase converts adipose tissue to oestrogen. Increased levels of oestrogen stimulates growth of ER+ breast cancers

19
New cards

SERMs

Selective oestrogen receptor modulatorsthat bind to estrogen receptors, acting as agonists in some tissues and antagonists in others.

20
New cards

SERDs

Selective osetrogen receptor degraders. Degrade ER alpha,

IM only

more side effects than SERMs

used after SERM or AI failure.

21
New cards

AIs

Aromatase inhibitors.

Inhibit aromatise enzymes (which convert androgens into oestrogen) and therefore stop oestrogen synthesis.

Preferred in post menopausal women

22
New cards

What is high dose methotrexate used in cancer therapy

>500mg/m2

23
New cards

What do you need to do when administering methotrexate for cancer therapy

24
New cards

methotrexate MOA

inhibits dihydrofolate reductase, so DNA synthesis can’t happen.

25
New cards

comon toxicities w high dose methotrexate

Blood disorders

immunosuppression

hepatotoxicity

renal toxicity

26
New cards

What is used to prevent methotrexate toxicity, and how do they do this

Folinic acid- dampens down the inhibition of DNA synthesis by methotrexate so there is not too much of this inhibiton. Helps nor,al cells to recover and reduce side effects. Also helps to eliminate methotrexate from the body

IV fluids - promote hydration and urine output to aid methotrexate elimination and prevent renal issues.

Sodium bicarbonare - alkalanises the urine. Methotrexate is less soluble in acidic urine. Sodium bicarb is used to increase methotrex solubility in the urine and aid elimination.

27
New cards

Why is it important to alkalinise the urine when taking high dose methotrexate

Acidic env’ts can cause crystallisation in renal tubules which can cause blockages and further damage to the kidneys.

28
New cards

common interactions with methotrexate.

  • Some antibiotics

eg penicillins- they are weak acids and also renally excreted, so can slow methotrexate metabolism as too acidic.

ciprofloxacin- displaces methotrexate from plasma proteins.

  • Theophylline

  • epilepsy medications

  • PPIs

  • Diuretics

  • NSAIDs (bc reduce renal blood flow)

  • some HTN meds

  • Alcohol

  • other immunosuppressants

29
New cards

methotrexate and aciclovir

interaction- increased risk of nephrotoxicity

30
New cards

alternative to PPI when giving high dose methotrexate

H2 receptor antagonist eg famotidine

31
New cards

MOA rituximab

Monoclonal antibody that targets CD20 on B lymphocytes. This leads to the depletion of B cells, by acting on CD20, promotes cell lysis.

32
New cards

what is rituxumab used in

types of lymphomas, leukemia , other cancers and autoimmune diseases.

33
New cards

does rituximab penetrate the CNS

Not under normal conditions.

34
New cards

What is glucoparidase, when is it used.

Methotrexate reversal agent - rapidly hydrolyses methotrexate into inactive non cytotoxic metabolites which arent metabolised by the kidney.

Used on AKI or methotrexate induced renal dysfunction.

Very high cost.

35
New cards

Why is there an interaction between azole antifungals and vincristine? What antifungal can you give instead?

Azole antifungals inhibit CYP3a4 , which metabolises vincristine. Therefore, they inhibit the metabolism of vincristine, and increase exposure, which leads to enhanced toxicity. (myelosuppression, neurotoxicity, inc risk of seizures)

alternative antifungal - amphotericin B.

36
New cards

Safeguards for intrathecal administration

  • clear labelling

  • separate preparation and storage areas

  • Administered only by trained professionals

  • CHECK- correct medicine, dose , patient , route- these checks recorded on intrathecal drug chart

  • collect from pharmacy ONLY when needed for administration

  • intrathecal register.

37
New cards

What is meant by a ‘Never event’

serious preventable incidents that should not occur if proper safety procedures are followed.

Unsafe and avoidable in healthcare settings

38
New cards

examples of never events

  • administration of intrathecal vincristine

  • overdose of insulin - misunderstood abbreviations / incorrect device

  • methotrexate overdose (prescribed as weekly dose).

39
New cards

What is TMPT? What does it do?

enzyme involved in metabolism of thiopurine drugs eg 6MP.

TPMT methylates 6MP into an inactive form- 6 methylmercaptopurine = less toxic and less active.

40
New cards

Why do you get variation in the activity of TPMT among different individuals

genetic polymorphism

41
New cards

Metabolism of 6MP

TPMT - methylates 6mp → 6 methylmercaptopurine = less toxic and less active.

HPRT- converts 6-MP into active metabolite= 6-TGN = gives drugs cytotoxic effects.

xanthine oxidase and other enzymes- inactivate 6mp further into other metabolites which are excreted.

42
New cards

consequences of low and intermediate TMPT activity.

Low= slow metabolism, higher levels of active metabolite 6TGN = increased risk of toxicity such as bone marrow suppression.

intermediate= moderate response , may need dose adjustments to avoid side effects.

43
New cards

What is meant by a heterozygous variant

has one normal allele and one mutated copy

44
New cards

Basic MOAs - immunotherapy, chemotherapy and targeted therapy

immunotherapy = modifies immune system to fight cancer

chemo- kills rapidly dividing cells

taergeted- targets specific molecules or pathways in cancer.

45
New cards

organs affected by immunotherapy

  • immune system, skin, lungs, gut , liver, endocrine

46
New cards

organs affected by chemotherapy

Bone marrow, GIT, hair folicles, liver

47
New cards

organs affected by targeted therapy

skin, liver, heart, blood vessels

48
New cards

Management of QT prolongation in cancer treatment

monitoring electrolytes

drug interactions

review choice of cancer therapy.

49
New cards

What is the BCR-ABL fusion gene (philadelphia chromosome)?

arises from reciprocal translocation between chromosomes 9 and 22. encodes an active tyrosine kinase that continually sends growth and survival signals to the cell.

50
New cards

BCR-ABL fusion gene in CML

disrupts 1st exon of ABL leading to sustained activation of tyrosine kinase and resistance to deactivating mechanisms. leads to uncontrolled cell growth and proliferation.

51
New cards

imatinib MOA

  • Tyrosine kinase inhibitor specifically targeting the BCR-ABL protein by competitively binding to the ATP binding site, blocking the ATP binding needed for kinase activity. This inhibits activation of PI3K, JAK/STAT and RAS/MAPK pathways to decrease proliferation, induce apoptosis, cause cell cycle arrest and slow disease progression.

52
New cards

Adverse effects of imatinib

  • myelosuppression

  • rashes/dry skin

  • GI

  • Oedema - report significant weight gain, monitor for swelling in ankles, face.

  • musculoskeletal pain

  • fatigue

53
New cards

Why can paracetamol sometimes cause issues in cancer treatment

  • Can mask fever and temperature- may need additional monitoring.

54
New cards

Lab diagnostics of TLS

  • uric acid inc

  • potassium inc

  • phosphorous inc

  • calcium dec

Levels 25% increase from baseline

55
New cards

monitoring for TLS

uric acid

creatinine

renal function

urine output and pH

electrolytes

calcium

phosphate

ECG

seizures

56
New cards

Allopurinol in the treatment of TLS

Xanthine oxidase inhibitor- stops body from making uric acid.

57
New cards

consequence of high uric acid

renal failure

58
New cards

rasburicase in treatment of TLS.

breaks down uric acid by catalysing the enzymatic oxidation of uric acid to an inactive and soluble metabolite, making it easier for the kidneys to excrete.

59
New cards

victim drugs of allopurinol and what this means

  • mercaptopurine

  • azathioprine

  • theophylline

are drugs that are metabolized by xanthine oxidase, thus their effectiveness may be increased or decreased when taken with allopurinol, requiring dosage adjustments.

60
New cards

management of TLS

  • hydration -IV fluids, increase fluid intake

  • consider diuretic eg furosemide if urine output is not adequate

  • Initiate rasburicase

  • monitor electrolytes

  • do not give potassium fluids

61
New cards

When is rasburicase contraindicated? what to do instead in established TLS

  • G6PD deficiency

  • gove allopurinol instead.

62
New cards

pre screening requirements before starting treatment with 6mp

TPMT levels , may affect dosing.

63
New cards

monitoring with treatment of 6mp

  • FBC weekly until stable dose, then every 2-4wks.

  • LFTs

  • renal function

  • tpmt

  • monitor for signs of infection

  • GI sx

Monitor 2,4,8,12 weekly then once stable every year.

64
New cards

What does it mean if someone has a high level of 6TGN while on treatment with 6MP?

indicates increasef efficacy but also increased toxicity.

dose reduction needed if too toxic

65
New cards

what genetic factors may contribute to high levels of 6TGN in patient undergoing treatment with 6mp?

  • Heterozygous mutant of TMPT- slower metabolism of 6MP leads to higher levels of 6-TGN. (tmpt normally inactivates 6mp, preventing int from conversion into cytotoxic metabolites such as tgn)

66
New cards

what can happen with too much TGN

bone marrow toxicity

blood disorders

67
New cards

What are non-synonymous mutations

alters the amino acid sequence of a protein

68
New cards

What are synonymous mutations?

Occur in DNA sequence, but do not alter the AA sequence because the changes in the sequence does not change the codon that specifies the amino acid

AKA silent mutation.

69
New cards

Nonsense mutation

change in DNA that causes a protein to terminate/ end its translation earlier than expected

= stop mutation

70
New cards

exon

a segment of DNA or RNA that codes for a protein. Exons are typically spliced together during the processing of the precursor mRNA.

71
New cards

intron

Non coding section within a gene that is removed during RNA splicing before translation to proteins.

72
New cards

intragenic single nucleotide polymorphism

genetic variation where a single nucleotide base changes within a gene that may or may not affect protein function.

can lead to expression of genes that are silent.

73
New cards

D538G mutation - why does it lead to resistance to endocrine therapy?

  • mutation in the oestrogen receptor alpha gene.

    causes conformational change to an active shape even w/o oestrogen.

  • when endocrine therapies are used, receptor continues to stimulate cell growth.

74
New cards

Why are tubulin pathways potential targets for cancer drug design

they are often overexpressed in various cancers. They are involved in several hallmarks of cancer and contribute to uncontrolled proliferation, inhibiting apoptosis, and immune evasion

their contribution to the progression of cancer makes them suitable targets for treatment.

75
New cards

the two types of mechanisms of resistance to immunotherapy

intrinsic and extrinisic mechanisms of resistance

Intrinsic- cancer cells alter processes relevant to immune recognition, signalling, expressiona dn DNA damage.

Extrinsic- external to tumour cells through immunological and non immunological interactions

76
New cards

Mechanisms of resistance to immunotherapy

impaired MHC presentation- can cause resistance to t cell mediated cytotoxicity

Poor DNA repair

epigenetic modifiers → changes to antigen processing , antigen presentation, immune evasion

Altered signalling pathways to impair anti tumour response

Persistent IFN- gamma can lead to therapy resistance

TREGS- regulatory Tcells in tumour micoenvironments - suppress effector T cells and APC, maintain immune status.

Tumour associated macrophages

Antigen masking and presentation -present inappropriate antigens for therapy.

77
New cards

contribution of tubulin genes and pathways involved in the immune escape of cancer cells

  • tubulin interacts with actin - regulates cell shape, migration and invasion, so changes to tubulin could enhance migration and aid immune escape and thus metastasis

78
New cards

Who can prescribe cycle one of chemotherapy?

Consultant or appropriatelt credentialed clinician ONLY

Others can only prescribe chemo that has already been initiated.

79
New cards

vegan vitamin d supplement option

ergocalciferol

80
New cards

physiological changes associated with low testosterone

  • weight gain

  • night sweats

  • sleep problems

  • bone loss

  • fatigue

81
New cards

psychological changes assoc w low testosterone

Mood changes

depression

anxiety

difficulty concentrating

low self esteem

82
New cards

What can help hot flushes caused by low testosterone and how does it do this

  • sage. mimics oestrogen in the body.

83
New cards
84
New cards

side effects of goseralin treatment

myalgia- muscle and joint pain

myosiris- inflammation of muscle

fatighe

neuropathy that could impact muscle strength

increased risk of osteoporosis.

85
New cards

MOA - docetaxel

Disrupts microtubules in cells so they cannot grow and divide properly, leading to death of these cancer cells.

86
New cards

role of dexamethasone / steroids in cancer therapy

reduce inflammation

prevent fluid retention

reduce nausea

87
New cards

role of filgrastim in cancer therapy

boosts WBCs - encourages bone marrow to produce more WBCs.

protect from infection and help immune recovery from chemo.

88
New cards

role of metoclopramide in cancer therapy

anti emetic

speeds up digestion to empty stomach more quick;y

acts on brains nausea control centre- crosses BBB - careful parkinsons , schizo.

89
New cards

immediate management of neutropenic sepsis

blood cultures

IV Abx

Tazocin 4.5g QDS

Gentamicin IV - DO NOT USE NEPHROTIC ABX LIKE THIS IF PT ON NEPHROTOXIC CHEMO.

high flow oxygen if sats below 94

IV fluids

check serum lactate- assess tissue hypoperfusion/ early septic shock

monitor urine outpit

dailt FBC, U&E, LFT, renal function

90
New cards

Self monitoring of thrombocytopaenia

unusual bruising, bleeding

avoid injury

91
New cards

Management of chemo induced thrombocytopaenia

  • platelet transfusion

  • growth factors

  • Changes in chemotherapy regimen

92
New cards

Key steps in metastatic spinal cord compression pathway

  • Diagnosis - imaging

  • Emergency care management - steroids, pain

  • Surgerym radio, or systemic therapy 

  • Rehab and supportive care

93
New cards

some of the key medicines used in metastatic spinal cord compression management

  • corticosteroifs

  • pain- opioids, NSAIDSm neuropathic pain agents eg gabapentin for nerve pain

  • bone strengthening - bisphosphonares, denosumab

  • PPIs, laxatives etc to manage symptoms.

94
New cards

risk factors for frailty

  • age

  • lower BMI

  • Low excercise

  • polypharmacy

  • mental health issues- ie depression

  • cognitive impairment - dementia etc

  • poor nutrition

  • chronic disease

  • social isolation/ loneliness

95
New cards

Alternative therapies to manage pain/ anxiety/ depression

  • st johns wort

  • psilocybin

  • cbd oil

  • accupuncture

  • massages

  • taking therapy

  • therapy animals

  • etc

96
New cards

Dabrafenib MOA

ATP competitive inhibitor of mutant BRAF kinases which inhibits its kinase activity, therefore dec downstream MEK and ERK phosphorylation → inducing cell cycle arrest and apoptosis.

97
New cards

trametinib MOA

inhibitor of MEK1 and MEK 2. binds outside of ATP binding pocket - locks it into inactive conformation → prevents ERK phosphorylation.
Reduces proliferation , induces cell cycle arrest and triggers apoptotic pathways.

98
New cards

why are dabrafenib and trametinib good to use in combination therapy

Together they provide more complete pathway inhibition

They block two points in the MAPK pathway (BRAF and MEK), improving efficacy and reducing resistance compared to monotherapy.

99
New cards

side effect profile of trametinib

  • skin reactions - regular monitoring - prevent secondary infection if necessary.

  • GI - diarrhoea, ab pain, nausea

  • fatiguem peripheral oedema , fever

  • CV- reduced left vent ej fraction - baseline echocardiogram, then every 4-12wks

  • HTN- regular monitoring

  • Occular side effects- retinopathy , blurred vision - urgent referral if sx develop

  • pulmonary - pneumonitis - rare - look out for new cough/ breathlessness - imaging / pulmonary referral if applicable

100
New cards

canabis oil and chemotherapeutics

  • may mask sx/ side effects of medication

  • no clinical evidence for efficacy

  • can interfere with other chemotherapeutics